Effects of long-acting release octreotide on glucose homeostasis in acromegaly patients after trans-sphenoidal surgery

What Was Tested

The paper reports a study of Octreotide, published as a clinical trial.

The present study was aimed to investigate glucose homeostasis and insulin secretion in acromegalic patients during octreotide-long acting release (LAR) therapy and designed as an observational prospective study. 18 acromegalic patients who had undergone trans-sphenoidal surgery with active disease were included.

Why It Was Studied

These patients received oral glucose tolerance test (OGTT) before, 21 days after, and 1 year after octreotide-LAR treatment.

Primary outcomes were changes in glucose levels and insulin secretion during an OGTT.

Who Took Part

The study group was 18 patients.

By PubMed's age tags, the people studied were young adults, adults, middle-aged adults and older adults, both men and women.

All patients were treated with octreotide-LAR injection for 1 year.

How the Study Was Run

The methods mention a period of 1 year.

What Was Measured

These patients received oral glucose tolerance test (OGTT) before, 21 days after, and 1 year after octreotide-LAR treatment.

Primary outcomes were changes in glucose levels and insulin secretion during an OGTT.

The subject headings attached to it are Acromegaly, Blood Glucose, Glucose Tolerance Test, Homeostasis, Insulin, Octreotide and Sphenoid Bone.

What This Means in Plain Language

This is a clinical trial of Octreotide in 18 patients over 1 year.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2011 (Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme), a journal based in Germany.

More context: the Octreotide compound page, all human trials.